We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+10.43%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$260M
AUM Growth
+$45.7M
Cap. Flow
+$28M
Cap. Flow %
10.77%
Top 10 Hldgs %
28.77%
Holding
76
New
17
Increased
25
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$6.57M
2
MRK icon
Merck
MRK
+$6.28M
3
AZN icon
AstraZeneca
AZN
+$5.4M
4
COR icon
Cencora
COR
+$5.05M
5
CI icon
Cigna
CI
+$4.33M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.1M
2
UHS icon
Universal Health Services
UHS
+$6.51M
3
CAH icon
Cardinal Health
CAH
+$5.01M
4
SNN icon
Smith & Nephew
SNN
+$3.81M
5
UNH icon
UnitedHealth
UNH
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 93.84%
2 Energy 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
26
McKesson
MCK
$105B
$4.67M 1.8%
35,000
+17,813
+104% +$2.61M
ZBH icon
27
Zimmer Biomet
ZBH
$18.5B
$4.46M 1.71%
41,200
+22,869
+125% +$2.49M
ALGN icon
28
Align Technology
ALGN
$12.3B
$4.45M 1.71%
13,000
-5,000
-28% -$1.49M
CI icon
29
Cigna
CI
$72.4B
$4.25M 1.63%
+25,000
New +$4.33M
ILMN icon
30
Illumina
ILMN
$29.1B
$4.19M 1.61%
15,420
-5,140
-25% -$1.31M
QGEN icon
31
Qiagen
QGEN
$8.81B
$4.16M 1.6%
108,451
+37,722
+53% +$1.39M
SRPT icon
32
Sarepta Therapeutics
SRPT
$1.92B
$3.96M 1.52%
30,000
– –
BLUE
33
DELISTED
bluebird bio
BLUE
$3.92M 1.51%
1,930
+1,158
+150% +$2.64M
SAGE
34
DELISTED
Sage Therapeutics
SAGE
$3.91M 1.5%
25,000
+10,000
+67% +$1.57M
ESRX
35
DELISTED
Express Scripts Holding Company
ESRX
$3.86M 1.48%
+50,000
New +$3.75M
ALXN
36
DELISTED
Alexion Pharmaceuticals
ALXN
$3.73M 1.43%
30,000
– –
A icon
37
Agilent Technologies
A
$42.2B
$3.71M 1.43%
60,000
+20,000
+50% +$1.3M
LOXO
38
DELISTED
Loxo Oncology, Inc
LOXO
$3.47M 1.33%
20,000
+2,500
+14% +$376K
DGX icon
39
Quest Diagnostics
DGX
$26.2B
$3.3M 1.27%
+30,000
New +$3.13M
BHC icon
40
Bausch Health
BHC
$2.33B
$3.25M 1.25%
140,000
+10,000
+8% +$207K
LHCG
41
DELISTED
LHC Group LLC
LHCG
$3M 1.15%
35,000
– –
RDY icon
42
Dr. Reddy's Laboratories
RDY
$10.4B
$2.9M 1.11%
450,000
+171,435
+62% +$1.08M
TSRO
43
DELISTED
TESARO, Inc.
TSRO
$2.67M 1.03%
60,000
+31,729
+112% +$1.54M
CLVS
44
DELISTED
Clovis Oncology, Inc.
CLVS
$2.5M 0.96%
+55,000
New +$2.67M
CELG
45
DELISTED
Celgene Corp
CELG
$2.38M 0.92%
+30,000
New +$2.49M
NVO
46
Novo Nordisk
NVO
$207B
$2.31M 0.89%
+100,000
New +$2.38M
WMGI
47
DELISTED
Wright Medical Group Inc
WMGI
$2.2M 0.85%
+84,900
New +$1.94M
AGIO icon
48
Agios Pharmaceuticals
AGIO
$1.95B
$2.11M 0.81%
25,000
+4,981
+25% +$434K
CRSP icon
49
CRISPR Therapeutics
CRSP
$5.23B
$2.06M 0.79%
+35,000
New +$1.99M
EVHC
50
DELISTED
Envision Healthcare Holdings Inc
EVHC
$1.98M 0.76%
45,000
-60,000
-57% -$2.46M
1
2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Sivik Global Healthcare's Q2 2018 Portfolio in Review

As of Q2 2018, Sivik Global Healthcare held 76 positions worth $260M, up 21% from $214M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Sivik Global Healthcare deployed $28M of net new capital in Q2 2018, opening 17 new positions and adding to 25 existing holdings. Its largest new stake was Eli Lilly: 80,000 shares worth $6.83M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.46M trimmed.

  • Sivik Global Healthcare's largest Q2 2018 buy was Eli Lilly: 80,000 shares worth $6.83M.
  • Sivik Global Healthcare added most to Cencora in Q2 2018, an estimated $5.05M increase.
  • Sivik Global Healthcare's biggest Q2 2018 reduction was UnitedHealth, cutting an estimated $3.46M.
  • Sivik Global Healthcare fully exited AbbVie in Q2 2018, selling an estimated $7.1M.
  • Sivik Global Healthcare's ten largest holdings make up 29% of its $260M portfolio in Q2 2018.
  • Sivik Global Healthcare opened 17 new positions and closed 15 in Q2 2018.
  • Sivik Global Healthcare's portfolio value rose 21% quarter-over-quarter to $260M.

Based on Sivik Global Healthcare's 13F filing for Q2 2018, filed 6 Aug 2018.